Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
We evaluated metabolic and clinical features of 71 HIV-infected patients with lipodystrophy by comparing them with 213 healthy control subjects, matched for age and body mass index, from the Framingham Offspring Study. Thirty HIV-infected patients without fat redistribution were compared separately with 90 matched control subjects from the Framingham Offspring Study. Fasting glucose, insulin, and lipid levels; glucose and insulin response to standard oral glucose challenge; and anthropometric measurements were determined. HIV-infected patients with lipodystrophy demonstrated significantly increased waist-to-hip ratios, fasting insulin levels, and diastolic blood pressure compared with controls. Patients with lipodystrophy were more likely to have impaired glucose tolerance, diabetes, hypertriglyceridemia, and reduced levels of high-density lipoprotein (HDL) cholesterol than were controls. With the exception of HDL cholesterol level, these risk factors for cardiovascular disease (CVD) were markedly attenuated in patients without lipodystrophy and were not significantly different in comparison with controls. These data demonstrate a metabolic syndrome characterized by profound insulin resistance and hyperlipidemia. CVD risk factors are markedly elevated in HIV-infected patients with fat redistribution.
Hadigan
C
C
Neuroendocrine Unit, and Combined Program in Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, Boston, MA 02114, USA.
Meigs
J B
JB
Corcoran
C
C
Rietschel
P
P
Piecuch
S
S
Basgoz
N
N
Davis
B
B
Sax
P
P
Stanley
T
T
Wilson
P W
PW
D'Agostino
R B
RB
Grinspoon
S
S
D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002318:Cardiovascular Diseases / Q000209:etiology*; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D008060:Lipodystrophy / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D001786:Blood Glucose; D008076:Cholesterol, HDL; D017320:HIV Protease Inhibitors; D007328:Insulin; D008055:Lipids